Literature DB >> 25440987

Reduced radiation tolerance of penile structures associated with dose-escalated hypofractionated prostate radiotherapy.

Andrew M McDonald1, Christopher B Baker2, Kiran Shekar3, Richard A Popple4, Grant M Clark4, Eddy S Yang4, Rojymon Jacob4, Robert Y Kim4, John B Fiveash4.   

Abstract

OBJECTIVE: To investigate the effect of hypofractionated external beam radiation therapy (RT) on sexual function in patients treated for localized prostate cancer, and also to determine the effect of radiation dose to the penile bulb or crura of the corpus cavernosum on sexual function outcome.
MATERIALS AND METHODS: Forty-one patients treated with hypofractionated RT without androgen deprivation were prescribed 67.6-70.2 Gy to the prostate, delivered in 26-28 fractions. The primary endpoint was erectile dysfunction (ED) category based on the Sexual Health Inventory for Men (SHIM) score closest to 2 years from RT. The penile bulb and crura were contoured and mean radiation dose calculated for each structure.
RESULTS: The mean pretreatment SHIM score was 19.8, and the mean posttreatment SHIM score was 15.1. The ED category was decreased by ≥ 2 in 50% of patients with a mean penile bulb of >20 Gy compared with that in 9% of patients with a mean penile bulb dose of ≤ 20 Gy (P = .003). Mean dose to the crura was highly correlated with mean dose to the penile bulb (Pearson correlation = 0.842; P <.001) but did not reach statistical significance as a predictor of ED after radiation.
CONCLUSION: Radiation dose to the penile bulb is predictive of posttreatment ED in patients treated with dose-escalated hypofractionated prostate RT. The cutpoint at which this effect was observed with this treatment is substantially lower than the previous reports.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25440987      PMCID: PMC4516167          DOI: 10.1016/j.urology.2014.07.060

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  17 in total

1.  Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction.

Authors:  R C Rosen; J C Cappelleri; M D Smith; J Lipsky; B M Peña
Journal:  Int J Impot Res       Date:  1999-12       Impact factor: 2.896

2.  Penile bulb imaging.

Authors:  Kent E Wallner; Gregory S Merrick; Mark L Benson; Wayne M Butler; Jeffrey Maki; Bryan G Tollenaar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-07-15       Impact factor: 7.038

3.  Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer.

Authors:  Felix Leborgne; Jack Fowler; José H Leborgne; Julieta Mezzera
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-07       Impact factor: 7.038

4.  Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study.

Authors:  Mack Roach; Kathryn Winter; Jeffrey M Michalski; James D Cox; James A Purdy; Walter Bosch; Xiao Lin; William S Shipley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-12-01       Impact factor: 7.038

5.  Early prostate cancer--which treatment do men prefer and why?

Authors:  Carmel N Anandadas; Noel W Clarke; Susan E Davidson; Patrick H O'Reilly; John P Logue; Lynne Gilmore; Ric Swindell; Richard J Brough; Guy D Wemyss-Holden; Maurice W Lau; Pradip M Javle; Vijay A C Ramani; James P Wylie; Gerald N Collins; Stephen Brown; Richard A Cowan
Journal:  BJU Int       Date:  2010-11-17       Impact factor: 5.588

6.  Is the α/β ratio for prostate tumours really low and does it vary with the level of risk at diagnosis?

Authors:  Jack F Fowler; Iuliana Toma-Dasu; Alexandru Dasu
Journal:  Anticancer Res       Date:  2013-03       Impact factor: 2.480

7.  Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer.

Authors:  Alan Pollack; Gail Walker; Eric M Horwitz; Robert Price; Steven Feigenberg; Andre A Konski; Radka Stoyanova; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; Charlie Ma; Mark K Buyyounouski
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

8.  Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study.

Authors:  Arnold L Potosky; William W Davis; Richard M Hoffman; Janet L Stanford; Robert A Stephenson; David F Penson; Linda C Harlan
Journal:  J Natl Cancer Inst       Date:  2004-09-15       Impact factor: 13.506

9.  Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience.

Authors:  Patrick A Kupelian; Twyla R Willoughby; Chandana A Reddy; Eric A Klein; Arul Mahadevan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-06-04       Impact factor: 7.038

Review 10.  Erectile dysfunction after radiotherapy for prostate cancer: a model assessing the conflicting literature on dose-volume effects.

Authors:  E Rivin del Campo; K Thomas; V Weinberg; M Roach
Journal:  Int J Impot Res       Date:  2013-06-20       Impact factor: 2.896

View more
  4 in total

1.  Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial.

Authors:  Julia Murray; Sarah Gulliford; Clare Griffin; Anna Wilkins; Isabel Syndikus; John Staffurth; Miguel Panades; Christopher Scrase; Chris Parker; Vincent Khoo; Jamie Dean; Helen Mayles; Philip Mayles; Simon Thomas; Olivia Naismith; Helen Mossop; Clare Cruickshank; Emma Hall; David Dearnaley
Journal:  Clin Transl Radiat Oncol       Date:  2019-12-31

Review 2.  Hypofractionated radiotherapy for localized prostate cancer.

Authors:  Stefan Höcht; Daniel M Aebersold; Clemens Albrecht; Dirk Böhmer; Michael Flentje; Ute Ganswindt; Tobias Hölscher; Thomas Martin; Felix Sedlmayer; Frederik Wenz; Daniel Zips; Thomas Wiegel
Journal:  Strahlenther Onkol       Date:  2016-09-14       Impact factor: 3.621

3.  Association between EBRT dose volume histograms and quality of life in prostate cancer patients.

Authors:  Anna Boladeras; Ferran Ferrer; Valentin Navarro; Rodolfo De Blas; Oriol Cunillera; David Mateo; Cristina Gutierrez; Evelyn Martinez; Salvador Villà; Joan Pera; Montse Ferrer; Ferran Guedea
Journal:  Rep Pract Oncol Radiother       Date:  2018-08-13

4.  Advantages of TRUS-based delineation for high-dose-rate prostate brachytherapy planning.

Authors:  Heloise Lavoie-Gagnon; Andre-Guy Martin; Eric Poulin; Louis Archambault; Laurie Pilote; William Foster; Eric Vigneault; Damien Carignan; Frederic Lacroix
Journal:  J Contemp Brachytherapy       Date:  2022-02-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.